Skip to contentM
Marimed Inc.
M
MRMDMarimed Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$38.90M$38.90Mderived+8.6% vs Q4 2022 Net Income-$10.17M-$10.17MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marimed Inc. · CIK 1522767 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$17,317,000+9.5% Operating Incomederived$2,411,000−21.9% Operating Cash Flowderived$3,234,000+86.2% Free Cash Flowderived-$2,147,000N/M Margins · derivedGross margin44.5%+0.4 pt vs Q4 2022
Operating margin6.2%−2.4 pt vs Q4 2022
Net margin-26.1%−39.4 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 7, 2024 · 67 d after period end